MX354717B - Moleculas de union novedosas con actividad antitumoral. - Google Patents

Moleculas de union novedosas con actividad antitumoral.

Info

Publication number
MX354717B
MX354717B MX2014011066A MX2014011066A MX354717B MX 354717 B MX354717 B MX 354717B MX 2014011066 A MX2014011066 A MX 2014011066A MX 2014011066 A MX2014011066 A MX 2014011066A MX 354717 B MX354717 B MX 354717B
Authority
MX
Mexico
Prior art keywords
binding
binding molecule
peptide
poly
vector
Prior art date
Application number
MX2014011066A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011066A (es
Inventor
Brack Simon
Mourlane Frédéric
Toller Isabella
Woods Richard
Bertschinger Julian
Grabulovski Dragan
Schade Babette
Klupsch Kristina
Hachemi Helen
Original Assignee
Covagen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen Ag filed Critical Covagen Ag
Publication of MX2014011066A publication Critical patent/MX2014011066A/es
Publication of MX354717B publication Critical patent/MX354717B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014011066A 2012-03-16 2013-03-08 Moleculas de union novedosas con actividad antitumoral. MX354717B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12159938 2012-03-16
PCT/EP2013/054768 WO2013135588A1 (en) 2012-03-16 2013-03-08 Novel binding molecules with antitumoral activity

Publications (2)

Publication Number Publication Date
MX2014011066A MX2014011066A (es) 2015-03-09
MX354717B true MX354717B (es) 2018-03-16

Family

ID=47844323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011066A MX354717B (es) 2012-03-16 2013-03-08 Moleculas de union novedosas con actividad antitumoral.

Country Status (12)

Country Link
US (2) US9593314B2 (OSRAM)
EP (1) EP2825197B1 (OSRAM)
JP (1) JP6325463B2 (OSRAM)
KR (1) KR20140135251A (OSRAM)
CN (1) CN104284675B (OSRAM)
AU (1) AU2013231488B2 (OSRAM)
BR (1) BR112014022932A2 (OSRAM)
CA (1) CA2865597A1 (OSRAM)
MX (1) MX354717B (OSRAM)
NZ (1) NZ629283A (OSRAM)
RU (1) RU2627185C1 (OSRAM)
WO (1) WO2013135588A1 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
EP2752426A1 (en) * 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
EP3074424B1 (en) 2013-11-27 2025-02-12 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
JP2017504325A (ja) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス，インコーポレイテッド バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CN106211782B (zh) * 2014-03-17 2021-01-15 田边三菱制药株式会社 抗体-fynomer缀合物
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
WO2017120576A1 (en) * 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
KR102532256B1 (ko) 2016-11-21 2023-05-12 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
CN111886247A (zh) 2018-01-05 2020-11-03 Ac免疫有限公司 错折叠tdp-43结合分子
JP7350756B2 (ja) 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
RU2018111298A (ru) * 2018-03-29 2019-10-01 Закрытое Акционерное Общество "Биокад" Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
JP2022533432A (ja) 2019-05-23 2022-07-22 エイシー イミューン ソシエテ アノニム 抗ｔｄｐ－４３結合分子およびその使用
WO2020254540A1 (en) 2019-06-18 2020-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
EP4061830A1 (en) 2019-11-20 2022-09-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Archaeal peptide recombinase - a novel peptide ligating enzyme
WO2021116337A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
AR123165A1 (es) 2020-08-07 2022-11-02 Hoffmann La Roche Un método para la producción de composiciones protéicas
US20230322908A1 (en) 2020-08-14 2023-10-12 Ac Immune Sa Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
MX2024005876A (es) 2021-11-16 2024-05-29 Ac Immune Sa Moleculas novedosas para terapias y diagnostico.
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
KR20250004705A (ko) 2022-04-08 2025-01-08 에이씨 이뮨 에스에이 항-tdp-43 결합 분자
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20190126461A (ko) * 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
BRPI0515589A (pt) 2004-09-02 2008-07-29 Genentech Inc polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
EP2470556B1 (en) 2009-08-27 2018-05-30 Covagen AG Il-17 binding compounds and medical uses thereof
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
JP5667207B2 (ja) * 2009-12-14 2015-02-12 シル プロテインズ ゲーエムベーハーＳｃｉｌ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ リガンドへの結合能を有するヘテロ多量体修飾ユビキチンタンパク質の同定方法
NZ604003A (en) * 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
WO2012009705A1 (en) * 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof

Also Published As

Publication number Publication date
US20170281768A1 (en) 2017-10-05
JP6325463B2 (ja) 2018-05-16
CN104284675A (zh) 2015-01-14
JP2015516801A (ja) 2015-06-18
EP2825197A1 (en) 2015-01-21
CN104284675B (zh) 2017-07-18
CA2865597A1 (en) 2013-09-19
AU2013231488A1 (en) 2014-09-18
KR20140135251A (ko) 2014-11-25
WO2013135588A1 (en) 2013-09-19
AU2013231488B2 (en) 2017-12-07
US9593314B2 (en) 2017-03-14
NZ629283A (en) 2016-04-29
RU2627185C1 (ru) 2017-08-03
EP2825197B1 (en) 2018-06-06
BR112014022932A2 (pt) 2017-07-18
US20150047065A1 (en) 2015-02-12
MX2014011066A (es) 2015-03-09

Similar Documents

Publication Publication Date Title
MX354717B (es) Moleculas de union novedosas con actividad antitumoral.
ZA202308846B (en) Cx3cr1-binding polypeptides
MY171038A (en) Bispecific antigen binding molecules
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12013502531A1 (en) Bispecific t cell activating antigen binding molecules
MY177065A (en) 4-1bb binding molecules
WO2014004549A3 (en) Anti-mesothelin binding proteins
PH12015501672A1 (en) Binding molecules for bcma and cd3
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
PH12014501091A1 (en) Binding molecules for bcma and cd3
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
GB201008682D0 (en) Epitope tag for affinity based applications
TN2012000167A1 (en) Human il-23 antigen binding proteins
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
EP4282881A3 (en) Antibodies against csf-1r
MY164626A (en) Nucleic acid molecules encoding enzymes that confer disease resistance in jute
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands

Legal Events

Date Code Title Description
FG Grant or registration